{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:31:17Z","timestamp":1790209877517,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,3,3]],"date-time":"2006-03-03T00:00:00Z","timestamp":1141344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Lysosomal proteases are implicated in cancer progression and metastasis. In the current study, using subtraction cloning for genes that are differentially expressed in metastasis, the authors isolated a clone encoding ceroid lipofuscinosis, neuronal 2 (CLN2), which is a lysosomal serine protease defective in neuronal ceroid lipofuscinosis (NCL). Increased CLN2 activity has been reported in breast carcinoma and the antiapoptotic effect of another causative gene of NCL, ceroid lipofuscinosis, neuronal 1 (<jats:italic>CLN1<\/jats:italic>), is known.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The mRNA levels of <jats:italic>CLN2, CLN1<\/jats:italic>, and cathepsins B, D, H, and L were investigated in colorectal carcinoma patients with different clinical stages using real\u2010time quantitative reverse transcriptase polymerase chain reaction. A polyclonal antibody was raised against a recombinant CLN2 protein for immunoblotting and immunohistochemistry.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The mRNA levels of <jats:italic>CLN1<\/jats:italic> and cathepsins B, D, and L were significantly higher in metastatic lesions than in primary tumors. In the primary tumors, mRNA expressions of <jats:italic>CLN2<\/jats:italic> and cathepsin D were associated with advanced clinical stages (<jats:italic>P<\/jats:italic> &lt; .015 and <jats:italic>P<\/jats:italic> &lt; .031, respectively). Among the lysosomal enzymes examined, only the mRNA expression of <jats:italic>CLN2<\/jats:italic> in both the primary tumors of all patients and the pT3 tumors was correlated with the presence of liver metastases (<jats:italic>P<\/jats:italic> &lt; .0049 and <jats:italic>P<\/jats:italic> &lt; .029, respectively). The polyclonal antibody prepared in the current study demonstrated CLN2 overexpression by immunoblotting and immunohistochemistry.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The results indicate that there is a close correlation between <jats:italic>CLN2<\/jats:italic> and CLN1 expression and colorectal carcinoma progression and metastasis and suggest that they may be potential molecular targets. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21764","type":"journal-article","created":{"date-parts":[[2006,3,3]],"date-time":"2006-03-03T11:17:36Z","timestamp":1141384656000},"page":"1489-1497","source":"Crossref","is-referenced-by-count":14,"title":["Overexpression in colorectal carcinoma of two lysosomal enzymes, CLN2 and CLN1, involved in neuronal ceroid lipofuscinosis"],"prefix":"10.1002","volume":"106","author":[{"given":"Toshihiko","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,16]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2003.12.016"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mas.20001"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043453559"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2004.09.006"},{"key":"e_1_2_5_6_2","first-page":"3809","article-title":"Cysteine protease activities and tumor development in human colorectal carcinoma","volume":"49","author":"Sheahan K","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490305"},{"key":"e_1_2_5_8_2","first-page":"1137","article-title":"Stage\u2010specific increases in cathepsin B messenger RNA content in human colorectal carcinoma","volume":"51","author":"Murnane MJ","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_5_9_2","first-page":"253","article-title":"Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival","volume":"145","author":"Campo E","year":"1994","journal-title":"Am J Pathol."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(95)03930-U"},{"key":"e_1_2_5_11_2","first-page":"209","article-title":"Characterizing human colorectal carcinomas by proteolytic profile","volume":"11","author":"Murnane MJ","year":"1997","journal-title":"In Vivo."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.46.29190"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO;2-2"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(99)90094-1"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1054\/bjoc.1999.1098","article-title":"Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas","volume":"82","author":"del Re EC","year":"2000","journal-title":"Br J Cancer."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/172460080201700304"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2003.09.033"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.03.011"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2004.02.012"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5333.1802"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.4.576"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00500.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/376584a0"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90274-0"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.12.2786"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/172460080001500201","article-title":"A lysosomal pepstatin\u2010insensitive protease as a novel biomarker for breast carcinoma","volume":"152","author":"Junaid MA","year":"2000","journal-title":"Int J Biol Markers."},{"key":"e_1_2_5_27_2","first-page":"801","article-title":"The CLN3 gene is a novel molecular target for cancer drug discovery","volume":"62","author":"Rylova SN","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.0741478.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(02)00403-2"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.2207"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(85)90571-6"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1993.1523"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a022781"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.04.142"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008562200"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21764","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:46:56Z","timestamp":1760298416000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,16]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1002\/cncr.21764"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21764","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,16]]}}}